


Pharmaceutical Cost Reports

Fully Insured Individual and Group Coverage
(Excludes self-funded insured health groups)


2020 Q1 - Q4 RX Summary by Generic, Brand, and Over the Counter

	Count	Percent Of Claims	Allowed Amt	% of Dollar Volume
Generic	5,981,029	78%	\$ 134,862,207.09	13%
Brand	1,671,233	22%	\$ 877,976,428.43	86%
OTC	62,218	1%	\$ 4,409,312.70	0%
	7,714,480		\$ 1,017,247,948.22	

Percent of Claims



Percent of Dollar Volume



2020 Q1 - Q4 Top 10 Drug Categories

Drug Category	Charged	Allowed	Paid	Member Responsibility
Diabetic Therapies	\$ 155,371,371.59	\$ 117,835,111.99	\$ 105,802,087.27	\$ 11,886,264.69
Therapies for: Transplant Rejection, Arthritis, Autoimmune Diseases	\$ 136,341,764.12	\$ 106,669,996.93	\$ 102,576,746.85	\$ 3,762,483.56
Cancer Therapies	\$ 61,011,649.40	\$ 40,943,458.84	\$ 39,103,666.13	\$ 1,801,226.09
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 49,090,247.46	\$ 33,978,512.94	\$ 29,573,408.59	\$ 4,358,080.08
Asthma/Breathing Therapies	\$ 37,148,030.98	\$ 27,988,851.88	\$ 22,952,208.68	\$ 4,992,482.94
Therapies for: Alcohol Dependence, ADHD/Mental Alertness, Appetite Suppression, Neuromuscular Abnormalities, Glaucoma, Increase Bladder/Intestinal Functions	\$ 36,252,220.42	\$ 23,596,573.96	\$ 18,466,233.97	\$ 5,097,373.55
Therapies for: Fertility, Contraceptives, Anemia, Osteoporosis, Weight Loss, Excessive Hair Growth, Uterine Bleeding, Hormone-Dependent Tumors	\$ 30,268,101.18	\$ 19,549,703.24	\$ 15,764,204.09	\$ 3,805,323.96
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 25,453,324.12	\$ 18,695,516.37	\$ 15,931,332.90	\$ 2,753,720.37
Therapies for: Hormonal Imbalance, Thyroid Disorders, Kidney Disorders	\$ 22,939,795.38	\$ 18,612,369.16	\$ 17,691,893.90	\$ 672,121.69
Pain Therapies	\$ 43,467,469.33	\$ 14,305,157.63	\$ 11,126,331.23	\$ 3,173,280.68

2020 Q1 - Q4 Top 30 Drugs by Average Dollar Volume *

Trade Name	RX Type	Average Day Supply	Average Charged	Average Allowed	Average Paid	Average Member Responsibility
HAEGARDA C1 ESTERASE INHIBITOR SUBCUTANEOUS HUMAN	BRAND	28	\$ 80,212.61	\$ 57,738.21	\$ 57,426.78	\$ 311.43
MAVENCLAD	BRAND	24	\$ 70,128.50	\$ 58,593.21	\$ 55,478.50	\$ 3,114.71
HEMLIBRA	BRAND	26	\$ 64,145.81	\$ 54,310.48	\$ 52,877.95	\$ 377.08
KORLYM	BRAND	30	\$ 43,692.00	\$ 43,692.00	\$ 43,465.83	\$ 226.17
TAKHZYRO	BRAND	25	\$ 74,398.99	\$ 41,580.57	\$ 41,561.47	\$ 19.09
GATTEX	BRAND	30	\$ 114,951.76	\$ 41,646.72	\$ 41,344.17	\$ 302.55
PROCYSBI	BRAND	30	\$ 36,520.68	\$ 31,855.76	\$ 31,456.44	\$ 399.32
HARVONI	BRAND	28	\$ 34,774.02	\$ 27,502.41	\$ 25,432.14	\$ 2,070.26
KALYDECO	BRAND	28	\$ 28,074.10	\$ 23,913.28	\$ 23,823.77	\$ 89.51
TRIKAFTA	BRAND	27	\$ 28,868.63	\$ 23,871.77	\$ 23,509.09	\$ 352.47
SYMDEKO	BRAND	28	\$ 27,269.14	\$ 21,913.20	\$ 21,304.11	\$ 607.36
ORENITRAM	BRAND	28	\$ 38,218.37	\$ 21,090.37	\$ 20,968.72	\$ 121.65
ORKAMBI	BRAND	28	\$ 25,103.08	\$ 21,207.55	\$ 20,801.05	\$ 397.37
RETEVMO	BRAND	30	\$ 27,382.15	\$ 20,510.95	\$ 20,510.95	\$ -
PALYNZIQ	BRAND	29	\$ 23,528.82	\$ 20,659.89	\$ 20,160.79	\$ 499.10
STELARA	BRAND	38	\$ 24,706.08	\$ 20,397.08	\$ 19,999.16	\$ 362.13
UPTRAVI	BRAND	29	\$ 35,283.31	\$ 19,625.28	\$ 19,267.73	\$ 357.55
EPCLUSA	BRAND	28	\$ 24,398.83	\$ 20,045.14	\$ 18,979.62	\$ 827.46
VYNDAMAX	BRAND	30	\$ 23,837.09	\$ 18,993.30	\$ 18,867.83	\$ 125.47
SABRIL	BRAND	30	\$ 33,122.59	\$ 19,331.91	\$ 18,802.75	\$ 529.17
CABOMETYX	BRAND	26	\$ 23,029.70	\$ 18,868.58	\$ 18,659.90	\$ 208.69
POMALYST	BRAND	27	\$ 21,813.96	\$ 18,073.85	\$ 17,847.23	\$ 226.62
HETLIOZ	BRAND	30	\$ 20,441.77	\$ 17,638.57	\$ 17,534.87	\$ 103.70
LENVIMA	BRAND	26	\$ 23,961.94	\$ 16,274.71	\$ 16,220.80	\$ 53.91
SKYRIZI	BRAND	39	\$ 19,809.99	\$ 16,263.34	\$ 15,589.64	\$ 657.31
REVLIMID	BRAND	26	\$ 19,222.92	\$ 15,700.52	\$ 15,572.78	\$ 127.74
TAGRISSEO	BRAND	30	\$ 19,870.15	\$ 15,348.88	\$ 15,270.03	\$ 78.85
AFINITOR	BRAND	27	\$ 18,028.18	\$ 15,457.25	\$ 14,885.14	\$ 572.11

ELOCTATE	BRAND	28	\$ 18,341.94	\$ 14,856.97	\$ 14,706.97	\$ 90.00
STIVARGA	BRAND	23	\$ 17,756.69	\$ 14,698.21	\$ 14,691.39	\$ 6.82

*To be included in this table, at least 20 prescriptions for the drug must exist in the database.

2020 Q1 - Q4 Top 30 Drugs by Total Dollar Volume *

TradeName	RX Type	Total Charged	Total Allowed	Total Paid	Total Member Responsibility
HUMIRA	BRAND	\$ 104,504,836.48	\$ 84,349,305.76	\$ 80,337,450.13	\$ 3,680,818.64
STELARA	BRAND	\$ 47,065,082.77	\$ 38,856,432.36	\$ 38,098,405.15	\$ 689,850.19
ATORVASTATIN CALCIUM	GENERIC	\$ 36,669,403.11	\$ 1,702,622.33	\$ 644,369.28	\$ 1,059,489.79
ENBREL	BRAND	\$ 30,527,826.17	\$ 24,832,589.56	\$ 23,481,415.67	\$ 1,345,857.45
OZEMPIC	BRAND	\$ 22,928,046.49	\$ 18,142,330.50	\$ 16,744,486.94	\$ 1,378,600.28
NOVOLOG	BRAND	\$ 22,592,993.36	\$ 17,707,283.50	\$ 16,359,935.45	\$ 1,281,606.12
TRULICITY	BRAND	\$ 22,176,878.07	\$ 17,460,477.01	\$ 16,029,960.53	\$ 1,417,704.53
NORDITROPIN	BRAND	\$ 21,547,655.21	\$ 16,723,115.12	\$ 16,020,982.54	\$ 681,405.18
TRIKAFTA	BRAND	\$ 19,948,219.92	\$ 16,495,394.27	\$ 16,244,778.00	\$ 243,556.89
OMEPRAZOLE	GENERIC	\$ 19,575,218.43	\$ 898,501.63	\$ 132,102.31	\$ 766,966.50
VYVANSE	BRAND	\$ 19,323,405.95	\$ 15,257,703.65	\$ 11,959,015.53	\$ 3,276,621.42
OTEZLA	BRAND	\$ 18,470,922.10	\$ 15,156,022.54	\$ 13,811,356.03	\$ 1,284,266.72
COSENTYX	BRAND	\$ 18,316,651.16	\$ 14,424,738.74	\$ 13,652,917.56	\$ 697,982.02
ARIPIPIRAZOLE	GENERIC	\$ 17,341,725.75	\$ 509,385.21	\$ 253,010.81	\$ 256,443.65
VICTOZA	BRAND	\$ 16,215,023.86	\$ 12,720,619.18	\$ 11,932,451.37	\$ 765,037.70
ROSUVASTATIN CALCIUM	GENERIC	\$ 15,174,241.08	\$ 680,399.97	\$ 311,517.04	\$ 369,592.76
JARDIANCE	BRAND	\$ 14,219,830.35	\$ 11,236,217.03	\$ 9,906,254.37	\$ 1,326,125.21
DUPIXENT	BRAND	\$ 13,615,258.72	\$ 10,869,088.12	\$ 9,672,943.40	\$ 1,039,177.49
BIKTARVY	BRAND	\$ 13,560,031.90	\$ 11,094,734.09	\$ 9,934,152.54	\$ 1,160,362.09
PANTOPRAZOLE SODIUM	GENERIC	\$ 13,174,678.71	\$ 691,127.79	\$ 126,958.88	\$ 564,627.00
TRESIBA	BRAND	\$ 13,168,334.86	\$ 10,276,588.22	\$ 9,372,085.28	\$ 902,647.87
ELIQUIS	BRAND	\$ 12,887,432.68	\$ 10,153,246.54	\$ 8,678,263.91	\$ 1,468,867.94
VENLAFAXINE HYDROCHLORIDE	GENERIC	\$ 10,626,779.71	\$ 1,477,586.04	\$ 718,103.89	\$ 759,129.05
REVLIMID	BRAND	\$ 10,495,715.46	\$ 8,572,483.75	\$ 8,502,737.70	\$ 69,746.05
JANUVIA	BRAND	\$ 10,437,757.08	\$ 8,129,492.60	\$ 7,242,055.21	\$ 887,463.02
MONTELUKAST SODIUM	GENERIC	\$ 10,147,130.61	\$ 669,956.84	\$ 215,565.31	\$ 454,727.21
TECFIDERA	BRAND	\$ 10,136,142.84	\$ 8,220,827.56	\$ 7,873,238.00	\$ 323,863.38

ONDANSETRON	GENERIC	\$ 10,096,378.15	\$ 358,354.47	\$ 117,319.14	\$ 241,767.87
XARELTO	BRAND	\$ 10,000,414.10	\$ 7,848,671.57	\$ 6,739,605.07	\$ 1,104,741.91
SYMBICORT	BRAND	\$ 9,873,832.31	\$ 7,721,874.38	\$ 6,150,383.21	\$ 1,569,837.14

* To be included in this table, at least 20 prescriptions for the drug must exist in the database.

2020 Q1 - Q4 RX Counts by Plan / Product Type

Plan Type	Plan Description	Product Type	Product Description	RXcount	Charged Per Script	Allowed Per Script	Paid Per Script	Mbr Resp Per Script
2	PPO	1	Medical/Health	5,097,722	\$ 302.45	\$ 163.25	\$ 144.20	\$ 18.74
7	Qualified High Deductible PI	1	Medical/Health	1,011,638	\$ 342.95	\$ 185.31	\$ 143.57	\$ 41.32
4	POS	1	Medical/Health	484,871	\$ 294.38	\$ 156.61	\$ 140.01	\$ 16.60
3	HMO	1	Medical/Health	78,450	\$ 500.23	\$ 261.89	\$ 237.77	\$ 24.16
7	Qualified High Deductible PI	2	Ancillary Drug	31	\$ 215.90	\$ 110.10	\$ 88.51	\$ 22.52
4	POS	2	Ancillary Drug	1	\$ 10.84	\$ 5.89	\$ -	\$ 5.89

2020 Q1 - Q4 PMPM RX Costs

	Member Months	Allowed	Average PMPM
Age <= 14	1,005,374	\$ 56,411,698.05	\$ 56.11
Age 15-24	878,732	\$ 94,695,691.48	\$ 107.76
Age 25-44	1,949,088	\$ 292,024,637.43	\$ 149.83
Age 45-64	2,027,019	\$ 589,224,566.81	\$ 290.69

Average Allowed Charge PMPM by Age Group

